Hypothyroidism associated with nivolumab treatment of unresectable malignant melanoma

Clin Exp Dermatol. 2017 Mar;42(2):217-218. doi: 10.1111/ced.13028. Epub 2017 Jan 4.

Authors

K Imafuku¹, K Yoshino¹, K Yamaguchi¹, S Tsuboi¹, K Ohara¹, H Hata²

Affiliations

¹ Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagoame, Bunkyo-ku, Tokyo, 113-8677, Tokyo, Japan.
² Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

PMID: 28052364
DOI: 10.1111/ced.13028

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal / adverse effects*
Antineoplastic Agents / adverse effects*
Humans
Hypothyroidism / chemically induced*
Male
Melanoma / drug therapy*
Nivolumab
Rectal Neoplasms / drug therapy*
Thyroid Hormones / blood

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Thyroid Hormones
Nivolumab